HopeStage
Back to all studies
Recruitment unclearEUCTR 2004-001308-11

Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies

This historical record does not confirm current site availability.

Historical research recordSpainBipolarity
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
Spain
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruitment unclear
Enrollment listed in the registry
0
Sponsor
Lilly.S.A.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Spain
Age range
Not clearly listed
Official registry ID
EUCTR 2004-001308-11
Official title
Show the full official title

Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Status unknown

Spain

Registry details
Historical country statuses

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lilly.S.A.

Want to explore more studies?

Explore studies